Is dabrafenib produced by Novartis?

Dabrafenib (Dabrafenib), produced by Novartis, is a kinase inhibitor used as an anti-tumor agent. It is formulated into hard gelatin capsules for the oral route of administration. Dabrafenib can be used as a single agent to treat patients with unresectable or metastatic melanoma with BRAF V600E mutations, as tested in trials approved by the U.S. Food and Drug Administration (FDA).

In combination with tramatinib, it is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutations detected in an FDA-approved test. Dabrafenibin combination with tramatinib for the treatment of braf v600-mutated metastatic non-small cell lung cancer in patients whose disease has progressed after systemic therapy. DabrafenibIn combination with tramatinibAdult and pediatric patients 6 years of age and older with unresectable or metastatic BRAF V600E-mutant solid tumors who have progressed on prior therapy and for whom there are no satisfactory alternative treatment options.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).